A-375

Malignant melanoma skin. Also called A375.

Cell Type:
Skin/Hair Epith.
Tissue Origin:
dermal
Species:
human
Research Area:
Cancer Research/Cell Biology
Dermatology/Tissue Engineering
Cell Characteristics:
Adherent

Recommended Media

Dulbecco's Modified Eagle Medium (DMEM) was developed in 1969 and is a modification of Basal Medium Eagle (BME) that differs from BME and MEM by the following characteristics:

  • Vitamins 4X greater than MEM. Vitamins and amino acids greater than BME
  • Types and quantities of amino acids greater than MEM and BME
  • Iron (ferric nitrate)

It is used in a wide range of mammalian cell culture applications.  The high glucose version is well suited to high density suspension culture. The low glucose formula is used for adherent dependent cells.

Storage = 2ºC to 8ºC

Liquid:
12-614 = 4.5 g/L glucose, without L-glutamine
12-604 = 4.5 g/L glucose, with L-glutamine
BE12-604/U1 = 4.5 g/L glucose, with Ultraglutamine I
12-914 = 4.5 g/L glucose, without L-glutamine (hybridoma screened)
12-917 = 4.5 g/L glucose, without L-glutamine or phenol red
12-709 = 4.5 g/L glucose and 25 mM HEPES, without L-glutamine
12-733= 4.5 g/L glucose, without L-glutamine or sodium pyruvate
12-741 = 4.5 g/L glucose, with L-glutamine, without sodium pyruvate

12-707 = 1.0 g/L glucose, without L-glutamine
12-708 = 1.0 g/L glucose and 25 mM HEPES, without L-glutamine

Powder:
15-614 = 4.5 g/L glucose, without L-glutamine or sodium pyruvate
15-604 = 4.5 g/L glucose, with L-glutamine or sodium pyruvate

Transfection Information

Lonza Optimized Protocol
Optimization Guideline
Filter:
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Protocol Kit Program Cells Efficiency Viable Cells Substrate Format Platform
V X-001 1e6 72% ±2 97% ±1 Plasmid (general) 2 µg 100 µl I/II/2b
SF FF-120 2e5 92% ±3 95% Plasmid (general) 0.4 µg 20 µl 4D X-Unit
SF FF-120 1e6 93% ±2 83% Plasmid (general) 2 µg 100 µl 4D X-Unit

Citations

Categories:
Transfection 
Authors:
Kreis S, Philippidou D, Margue C, Rolvering C, Haan C, Dumoutier L, Renauld JC, Behrmann I 
In:
PLoS ONE (2007) 2(12): e1300 
Categories:
Transfection 
Authors:
Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L, Linette G, Zhao H, Cornelius LA 
In:
Cancer Res (2006) 66(16): 7880-8 
Categories:
Transfection 
Authors:
Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, Robertson GP 
In:
Cancer Res (2006) 66(16): 8200-9